Vnitr Lek 2024, 70(6):370-375 | DOI: 10.36290/vnl.2024.074

Inflammation and the cardiovascular continuum

Peter Wohlfahrt
Pracoviště preventivní kardiologie, IKEM, Praha

The aim of this review article is to highlight the crucial impact of inflammation on the development and complications of arterial hypertension and cardiovascular diseases. The use of specific anti-inflammatory therapies, such as canakinumab or colchicine, indeed reduces cardiovascular risk but also increases the risk of infectious complications. Addressing traditional risk factors, such as arterial hypertension, dyslipidemia, obesity, and smoking, offers a safe pathway to reduce cardiovascular risk and systemic inflammation. In the realm of antihypertensive therapy, ACE inhibitors excel in their ability to reduce systemic inflammation. Since both arterial hypertension and systemic inflammation lead to vascular and organ damage, it is important to initiate antihypertensive therapy without delay and achieve early blood pressure control.

Keywords: hypertension, inflammation, cardiovascular prevention, fixed combinations, early treatment.

Accepted: September 19, 2024; Published: October 3, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Wohlfahrt P. Inflammation and the cardiovascular continuum. Vnitr Lek. 2024;70(6):370-375. doi: 10.36290/vnl.2024.074.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Nguyen MT, Fernando S, Schwarz N, et al. Inflammation as a Therapeutic Target in Atherosclerosis. J Clin Med. 2019;8. Go to original source... Go to PubMed...
    2. Mortensen Martin B, Jensen Jesper M, Rønnow Sand Niels P, et al. Association of Autoimmune Diseases With Coronary Atherosclerosis Severity and Ischemic Events. Journal of the American College of Cardiology. 2024;83:2643-2654. Go to original source... Go to PubMed...
    3. Fagundes NCF, Almeida A, Vilhena KFB, et al. Periodontitis As A Risk Factor For Stroke: A Systematic Review And Meta-Analysis. Vasc Health Risk Manag. 2019;15:519-532. Go to original source... Go to PubMed...
    4. Buckley DI, Fu R, Freeman M, et al. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151:483-495. Go to original source... Go to PubMed...
    5. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207. Go to original source... Go to PubMed...
    6. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine. 2017;377:1119-1131. Go to original source... Go to PubMed...
    7. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020;383:1838-1847. Go to original source... Go to PubMed...
    8. Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019;381:2497-2505. Go to original source... Go to PubMed...
    9. Wakabayashi K, Tsujino T, Naito Y, et al. Administration of angiotensin-converting enzyme inhibitors is associated with slow progression of mild aortic stenosis in Japanese patients. Heart Vessels. 2011;26:252-257. Go to original source... Go to PubMed...
    10. Bull S, Loudon M, Francis JM, et al. A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial). Eur Heart J Cardiovasc Imaging. 2015;16:834-841. Go to original source... Go to PubMed...
    11. Guzik TJ, Nosalski R, Maffia P, Drummond GR. Immune and inflammatory mechanisms in hypertension. Nat Rev Cardiol. 2024. Go to original source...
    12. Czesnikiewicz-Guzik M, Osmenda G, Siedlinski M, et al. Causal association between periodontitis and hypertension: evidence from Mendelian randomization and a randomized controlled trial of non-surgical periodontal therapy. Eur Heart J. 2019;40:3459-3470. Go to original source... Go to PubMed...
    13. Pietropaoli D, Cairo F, Citterio F, et al. Practical Guidelines for Patients with Hypertension and Periodontitis. High Blood Press Cardiovasc Prev. 2023;30:7-16. Go to original source... Go to PubMed...
    14. Awad K, Zaki MM, Mohammed M, Lewek J, Lavie CJ, Banach M. Effect of the Renin-Angiotensin System Inhibitors on Inflammatory Markers: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Mayo Clin Proc. 2022;97:1808-1823. Go to original source... Go to PubMed...
    15. Lee JG, Joo SJ, Kim SY, et al. Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction. PLoS One. 2023;18:e0281460. Go to original source... Go to PubMed...
    16. Madej A, Dąbek J, Majewski M, Szuta J. Effect of perindopril and bisoprolol on IL-2, INF-γ, hs-CRP and T-cell stimulation and correlations with blood pressure in mild and moderate hypertension. Int J Clin Pharmacol Ther. 2018;56:393-399. Go to original source... Go to PubMed...
    17. Ceconi C, Fox KM, Remme WJ, et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovascular Research. 2007;73:237-246. Go to original source... Go to PubMed...
    18. Strauss MH, Hall AS. Angiotensin Receptor Blockers Do Not Reduce Risk of Myocardial Infarction, Cardiovascular Death, or Total Mortality: Further Evidence for the ARB-MI Paradox. 2017;135:2088-2090. Go to original source... Go to PubMed...
    19. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874-2071. Go to original source... Go to PubMed...
    20. Rea F, Corrao G, Merlino L, Mancia G. Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. Eur Heart J. 2018;39:3654-3661. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.